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DOI 10.1016/j.ccr.2011.06.004SUMMARYTP53 missense mutations dramatically influence tumor progression, however, their mechanism of action is
still poorly understood. Here we demonstrate the fundamental role of the prolyl isomerase Pin1 in mutant
p53 oncogenic functions. Pin1 enhances tumorigenesis in a Li-Fraumeni mouse model and cooperates
with mutant p53 in Ras-dependent transformation. In breast cancer cells, Pin1 promotes mutant p53 depen-
dent inhibition of the antimetastatic factor p63 and induction of a mutant p53 transcriptional program to
increase aggressiveness. Furthermore, we identified a transcriptional signature associated with poor prog-
nosis in breast cancer and, in a cohort of patients, Pin1 overexpression influenced the prognostic value of p53
mutation. These results define a Pin1/mutant p53 axis that conveys oncogenic signals to promote aggres-
siveness in human cancers.INTRODUCTION
Mutations in the TP53 tumor suppressor gene are among the
most frequent genetic alterations in human cancers (Soussi
and Wiman, 2007). In addition to sporadic tumors, inherited
TP53 mutations are causative of Li-Fraumeni syndrome,
a disease characterized by an early onset of a broad tumor spec-
trum (Malkin et al., 1990). As a consequence of these mutations
p53 loses the ability to bind wild-type p53 responsive elementsSignificance
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Pin1 Amplifies Mutant p53 Gain of FunctionPivotal for mutant p53 gain of function is the formation of aber-
rant protein complexes perturbing the activity of the interacting
partners. For instance, mutant p53 contributes to malignant
phenotypes, such as migration and invasion or genomic insta-
bility, through binding and inactivating the antimetastatic factor
p63 and Mre11, respectively (Adorno et al., 2009; Song et al.,
2007). Although defective in sequence-specific DNA binding,
mutant p53 exerts its gain of function also altering
transcriptional regulation, based on aberrant interactions with
several transcription factors, such as VDR, NF-Y, and E2F, and
recruitment of transcriptional cofactors (Brosh andRotter, 2009).
Evidence from in vivo studies highlighted that efficient gain of
function of mutant p53 is associated with a transformed cellular
environment (Song et al., 2007; Soussi and Be´roud, 2001; Ter-
zian et al., 2008), supporting the notion that oncogenic stress
signaling could activate mutant p53 throughmechanisms similar
to those required to stimulate wild-type p53 (Song et al., 2007;
Terzian et al., 2008). To investigate and dissect the mechanisms
through which oncogenic signaling triggers mutant p53 activi-
ties, we focused on factors that might link cancer-related
signaling with mutant p53 functions. An intriguing candidate for
this role is the prolyl isomerase Pin1, that transduces phosphor-
ylation signaling into conformational changes affecting the func-
tions of its substrates (Lu and Zhou, 2007; Yeh and Means,
2007). We and others have previously identified this enzyme as
a critical regulator of wild-type p53 activities in cells exposed
to genotoxic stress (Mantovani et al., 2007; Zacchi et al., 2002;
Zheng et al., 2002). Despite Pin1 supporting wild-type p53 func-
tions, Pin1/mice do not develop tumors (Atchison et al., 2003).
Instead, Pin1 is frequently overexpressed in human tumors (Bao
et al., 2004) and has been shown to promote both Her2/Neu/Ras
and Notch1 dependent transformation of breast cells (Rustighi
et al., 2009; Wulf et al., 2004). Because several aspects of the
regulation of wild-type and mutant p53 proteins are similar (Ter-
zian et al., 2008), we reasoned that the role of Pin1 as a compo-
nent of physiologic checkpoint mechanisms may be subverted
during tumorigenesis, becoming a crucial amplifier of mutant
p53 oncogenic functions.RESULTS
Pin1 Enhances Tumorigenesis in a Mutant p53 Knockin
Mouse Model
To understand the impact of Pin1 on mutant p53 in tumorigen-
esis, we crossed mutant p53 knockin mice, bearing one knockin
allele for p53R172H (p53M/+) (Lang et al., 2004), with Pin1+/
mice (Atchison et al., 2003). Two cohorts of compound mice,
having either one or two knockin alleles with wild-type or
knock-out Pin1 genotypes (p53M/+Pin1+/+, p53M/+Pin1/, and
p53M/MPin1+/+, p53M/MPin1/), were generated and monitored.
Survival data for p53M/MPin1+/+ and p53M/+Pin1+/+ mice were
consistent with published results (Lang et al., 2004). Mice lacking
Pin1 displayed an increased median tumor-free survival in both
cohorts (Figures 1A and 1B). Although in the p53M/M cohort
absence of Pin1 caused variations only in the frequency of
some tumor types (see Table S1 available online), in the
p53M/+Pin1/ cohort, as compared to p53M/+Pin1+/+ mice, we
observed a markedly reduced tumor frequency, a reduced80 Cancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc.number of lymphomas and notably a complete absence of carci-
nomas (Figure 1C; Table S2).
We noticed amore pronounced effect due to lack of Pin1 in the
median survival time of the p53M/+ compared with the p53M/M
cohorts (7 weeks versus 4 weeks), which could be ascribed to
a contribution of Pin1 in the dominant negative activity of mutant
p53 over the remaining wild-type allele. However, in thismodel of
Li-Fraumeni syndrome, this activity is not evident, because the
survival curves of p53M/+ compared to p53+/ mice are indistin-
guishable (Lang et al., 2004). Moreover, albeit Pin1 enhances
complex formation between wild-type and mutant p53, this
does not abolish wild-type p53 transcriptional activity (data not
shown), likely due to a concomitant effect of Pin1 in potentiating
the function of unboundwild-type p53 (Zacchi et al., 2002; Zheng
et al., 2002). We also analyzed cohorts of p53+/Pin1+/+ and
p53+/Pin1/ mice and failed to observe any difference in
tumor-free survival, tumor frequency or spectrum (Figures S1A
and S1B and Table S2). Therefore, absence of Pin1 reduces
spontaneous tumorigenesis exclusively in mice expressing
mutant p53, suggesting that their cooperation in tumorigenesis
relies mainly on mutant p53 gain of function properties.
The genetic interaction between Pin1 andmutant p53 revealed
above, prompted us to dissect the underlying mechanisms.
Notably, Pin1 coimmunoprecipitated with p53 in tumor samples
from p53M/+Pin1+/+ mice (Figure S1C). Given that Pin1 specifi-
cally recognizes phosphorylated S/T-P motifs on its substrates,
our observation suggests that in tumor cells Pin1 might bind
mutant p53 in response to oncogenic signaling-mediated phos-
phorylation to regulate its function. To demonstrate this hypoth-
esis, we analyzed the effect of Pin1 on the ability of mutant p53 to
enhance Ras-induced transformation of primary cells (Lang
et al., 2004). Mouse embryo fibroblasts (MEFs) obtained from
p53M/MPin1+/+, p53M/MPin1/, p53/Pin1+/+, or p53/Pin1/
embryos were tested for anchorage-independent growth as well
as for their tumorigenic potential in vivo on retroviral transduction
of H-RasV12. Notably, p53M/MPin1+/+ cells formed 2-fold more
colonies in soft agar (Figure 1D, left) and when injected subcuta-
neously into immunocompromisedmice, they developed tumors
double in size as compared with either p53M/MPin1/ or p53/
cells (Figure 1D, right; Figure S1D). In H-RasV12-transduced
p53M/MPin1+/+ MEFs, coimmunoprecipitation (CoIP) experi-
ments allowed us to confirm the mutant p53-Pin1 interaction
(Figure S1E). In these cells, overexpression of H-RasV12 caused
upregulation of mutant p53 and Pin1 (Figure S1F), in agreement
with previous observations (Ryo et al., 2002). We next immuno-
precipitated mutant p53 from cellular lysates, normalized for p53
levels, and phosphorylation was probed with a phospho-S/T-P
specific antibody (MPM2). As shown in Figure 1E (left), H-
RasV12 overexpression increased phosphorylation of mutant
p53 on putative Pin1 binding motifs and, accordingly, its interac-
tion with Pin1 (Figure 1E, right).
Modulation of Pin1 levels in these cells and in thymic
lymphomas of the same genotypes did not affect mutant p53
protein accumulation (data not shown). This observation does
not exclude, however, that a contribution of Pin1 in mutant
p53 stabilization could be relevant during early steps of
tumorigenesis.
All together these findings suggest that Pin1 is necessary for the
ability of mutant p53 to promote both cell transformation and
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Figure 1. Pin1 Enhances Tumorigenesis in Mutant p53 Knockin Mice
(A) Tumor-free Kaplan-Meier survival curves of p53M/MPin1+/+ (n = 27) and p53M/MPin1/ (n = 22) mice cohorts (c2 = 4, p = 0.02, log rank Mantel-Haenszel test).
As a control, tumor-free Kaplan-Meier survival curves of p53+/+Pin1+/+ (n = 22) and p53+/+Pin1/ (n = 18) mice cohorts are shown.
(B) Tumor-free Kaplan-Meier survival curves of p53M/+Pin1+/+ (n = 19) and p53M/+Pin1/ (n = 17)mice cohorts (c2 = 5.4, p = 0.045, log rankMantel-Haenszel test).
As a control, tumor-free Kaplan-Meier survival curves of p53+/+Pin1+/+ (n = 22) and p53+/+Pin1/ (n = 18) mice cohorts are shown.
(C) Left: bar graph showing the proportion of mice of the indicated genotypes developing tumors. Right: pie graphs representing the proportion of tumor types in
p53M/+Pin1+/+ and p53M/+Pin1/ mice relative to tumor totals.
(D) Left: histogram of anchorage-independent growth of H-RasV12 transduced MEFs. Error bars indicate standard deviation (SD) (n = 3), P relative to
p53M/MPin1+/+ MEFs < 0.01 in all cases (two-tailed t test). Right: bar graph representing the volume of tumors originated by the indicated H-RasV12-transduced
MEFs injected in SCID NOD mice measured on sacrifice. The graph shows the average volume and SD of tumors from five mice injected for each cell type.
p < 0.01 (two-tailed t test). Representative images of tumors are shown below. Scale bar represents 0.2 cm.
(E) Left: western blot analysis of phosphorylated S-P or T-P sites (MPM-2 antibody) of normalized levels of immunoprecipitated p53R172H from p53M/MPin1+/+
MEFs infected with H-RasV12 (+) or empty vector (). NRA, not related antibody. Right: western blot analysis of pull-down assays with recombinant GST-Pin1
using cell lysates normalized as above. See also Figure S1 and Tables S1 and S2.
Cancer Cell
Pin1 Amplifies Mutant p53 Gain of Functiontumorigenicity and reveal a role for Pin1 as a key transducer of
oncogenic signaling, thus activating mutant p53 gain of function.
Pin1 Potentiates Mutant p53-Dependent Cell Migration
and Invasion of Human Tumor Cell Lines
To establish whether Pin1 could sustain mutant p53 oncogenic
function also in human cancer cells, we tested the ability ofPin1 to bind to endogenous mutant p53 in human breast
cancer cell lines MDA-MB-231 and SK-BR-3. In these cells,
mutant p53 is constitutively phosphorylated on some Pin1
binding sites (S33 and S46) (Zacchi et al., 2002; Zheng et al.,
2002) and able to interact with Pin1 in a phosphorylation-
dependent manner as judged by CoIP after treatment with l
phosphatase (Figures S2A–S2C). To verify whether H-RasV12Cancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc. 81
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Figure 2. Pin1 Amplifies Mutant p53 Pro-Migration Function
(A) Transwell migration assays of MDA-MB-231 cells transfected with the indicated siRNAs (RNAi). Error bars indicate SD (n = 3, *p < 0.001, two-tailed t test). The
effect on migration of two different Pin1 siRNA sequences (Pin1 [A] and Pin1 [B]) was analyzed. See Figure S2F for western blot analysis showing Pin1 andmutant
p53 depletion.
(B) Transwell migration assays of MDA-MB-231 cells transfected with control (C) or Pin1 (A) siRNA on transduction with retroviral vectors expressing siRNA
resistant HA-Pin1r, HA-Pin1r S67E (catalytically inactive) or empty vector (). Error bars indicate SD (n = 3, *p < 0.001, two-tailed t test). See Figure S2F for
western blot analysis of cell lysates.
(C) Lung colonization assays after tail vein injection of Pin1 depleted MDA-MB-231 cells. Left: histological analysis of lung colonization. Upper images: hema-
toxylin and eosin staining of representative sections of entire pulmonary lobes from mice inoculated with shLacZ-infected (control) or shPin1-infected cells (six
mice per each group), arrows indicate representative metastases. Lower images: immunohistochemical detection of Pin1 expression and inserts showing
a detailed view of the area indicated by the arrows (scale bars are indicated). Right: computer-aided assessment of percentage of lung tissue area occupied by
metastases. Data are reported in histograms as mean percentages ± standard error of the mean (Mann-Whitney rank sum test, *p = 0.009).
(D) Transwell migration assays of MDA-MB-231 cells transfected with p53 or control siRNA (C) on transduction with pMSCV () or pMSCV HA-Pin1 retroviral
vectors. Error bars indicate SD (n = 3, *p < 0.001, two-tailed t test). See Figure S2H for western blot analysis of cell lysates.
(E) Transwell migration assays of MDA-MB-231 cells cotransduced with pMSCV or pMSCV HA-Pin1 along with empty vector (), HA-p53K280, or HA-p53K280-
4M retroviral constructs. Specific depletion of endogenous mutant p53 was achieved transfecting an siRNA targeting the 30UTR (p53u). Error bars indicate
SD (n = 3, *p < 0.001, two-tailed t test). See Figure S2M for western blot analysis of cell lysates.
(F) Transwell migration assays of MDA-MB-231 cells cotransduced with pMSCV or pMSCV HA-Pin1 along with retroviral constructs expressing the indicated
mutant p53 constructs or empty vector (). Endogenous mutant p53 was knocked down as in (E). Error bars indicate SD (n = 3). *p value relative to HA-p53K280-
4M (two-tailed t test). pMSCV transduced cells: p < 0.001 for p53K280, p < 0.01 for p53K280-3MS46, p < 0.05 for p53K280-3MS315. pMSCVHA-Pin1 transduced
cells: p < 0.001 for p53K280 and p53K280-3MS46, p < 0.05 for p53K280-3MS315. See Figure S2N for western blot analysis of cell lysates.
See also Figure S2.
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Pin1 Amplifies Mutant p53 Gain of Functioncould affect mutant p53 phosphorylation, as well as interaction
with Pin1 also in human cells, we cotransfected H-RasV12 along
with p53K280 in H1299 p53 null cells. H-RasV12 enhanced
phosphorylation on two Pin1 binding sites on mutant p53
(S33 and S46) (Figure S2D) and its interaction with Pin1 (Fig-
ure S2E), in agreement with the results obtained in H-RasV12
transduced MEFs.82 Cancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc.Because induction of migration and invasion are critical
aspects of mutant p53 dependent metastatic phenotype
(Adorno et al., 2009; Muller et al., 2009), we evaluated whether
Pin1 could play a role in these processes. RNAi-mediated knock-
down of either mutant p53 or Pin1 significantly reduced cell
migration and invasion of MDA-MB-231 cells (Figure 2A; Figures
S2F and S2G). The effect of Pin1 on migration was specific and
Cancer Cell
Pin1 Amplifies Mutant p53 Gain of Functionrequired its enzymatic activity, because reintroduction of an
siRNA-resistant Pin1 construct (Pin1r), but not a catalytically
inactive Pin1 mutant (Pin1r S67E), restored migration (Figure 2B;
Figure S2H). The impact of Pin1 on promoting invasion and
metastasis was further evaluated in vivo, by injecting control-
or Pin1-depleted MDA-MB-231 cells intravenously into immuno-
compromised mice. The ability of Pin1 depleted cells to colonize
the lungs was drastically reduced (Figure 2C; Figure S2I).
We next asked whether Pin1 exerts these effects epistatically
by modulating mutant p53 functions. As shown in Figure 2D and
Figure S2J, Pin1 overexpression in MDA-MB-231 cells causes
a significant increase in cell migration and invasion, however,
simultaneous depletion of mutant p53 almost completely
abolished these effects. In order to test whether direct interac-
tion between Pin1 and mutant p53 is necessary, we generated
a modified form unable to bind to Pin1 (p53K280-4M) of the
endogenous mutant p53 (p53K280). In this construct alanines
replaced serine or threonine residues in the four S/T-P phos-
phorylation and Pin1 binding sites (S33, S46, T81, and S315)
(Mantovani et al., 2007), without perturbing the subcellular local-
ization (Figures S2K and S2L). We then compared the effect of
p53K280 and p53K280-4M on migration of MDA-MB-231 cells
in which endogenous mutant p53 was selectively depleted using
an siRNA targeting the 30UTR of its mRNA (p53u). Reintroduction
of an siRNA-resistant p53K280 resulted in complete rescue of
migration, whereas almost no effect was observed in cells
expressing p53K280-4M. Notably, on Pin1 overexpression, we
observed an increased migration in p53K280 but not in
p53K280-4M expressing cells (Figure 2E; Figure S2M).
To evaluate which of these four phosphorylation sites in
mutant p53 is important in promoting this phenotype, wild-type
amino acids were separately reintroduced into p53K280-4M on
each of the alanine substitutions and the resulting four different
p53K280-3M constructs were tested for the ability to rescue
cell migration on depletion of endogenous mutant p53. Only
constructs expressing mutant p53 with wild-type S46 or S315
phosphorylation sites allowed recovery of cell migration, with
p53K280-3M-S46 showing the stronger impact, and their effect
was even more evident when Pin1 was coexpressed (Figure 2F;
Figure S2N). These constructs were able to recover Pin1 binding
in CoIP experiments (Figure S2O) further confirming the impor-
tance of Pin1 interaction with these phosphorylation sites on
mutant p53 to promote cell migration.
Next, we wanted to test which kinases could be involved in
phosphorylating mutant p53 on S46. As shown in Figure S2P,
treatment of MDA-MB-231 cells with inhibitors of kinases,
some of which act downstream of Ras signaling, reduced phos-
phorylation of endogenous mutant p53 on S46.
Overall, these results strongly suggest that phosphorylation of
critical S/T-P sites in mutant p53, triggered by oncogenic
signaling, promotes Pin1 binding thus unleashing mutant p53
pro-migration activity.
Pin1 Impacts Mutant p53 Transcriptional Regulation
Mutant p53 was reported to enhance cell migration and invasion
by sequestering and inactivating the antimetastatic factor p63
(Adorno et al., 2009; Muller et al., 2009). Therefore, we asked
whether Pin1 could promote the mutant p53-p63 interaction.
CoIP assays in MDA-MB-231 cells showed that Pin1 overex-pression increased the association between endogenous p63
and mutant p53, whereas Pin1 downregulation reduced their
interaction (Figure 3A). Likewise, p53K280-4M did not efficiently
associate with p63 (Figure 3B), indicating that phosphorylation
on these sites and Pin1 binding are required for the interaction
with p63. Pin1 downregulation also reduced the interaction
between Smad2 and p63, which was shown to be required for
mutant p53 binding to p63 on TGF-b treatment (Adorno et al.,
2009) (Figure S3A).
Accordingly, on Pin1 overexpression, the transcriptional func-
tion of p63 was curbed, as judged from reduced expression of
p63 targetsCCNG2 andSharp-1 (Adorno et al., 2009) (Figure 3C);
an effect that was mutant p53-dependent because concomitant
downregulation ofmutant p53 caused their induction (Figure 3D).
Moreover, silencing of Pin1 caused upregulation of these and
other p63 target genes such as Dicer (Su et al., 2010). This effect
required the presence of p63, because their expression levels
decreased when Pin1 and p63 were simultaneously downregu-
lated (Figures S3B and S3C).
In vitro GST-Pin1 pull down and CoIP assays in MDA-MB-231
cells demonstrated that p63 binds Pin1 (Figure S3D), thus sug-
gesting that Pin1 could also affect directly p63 functions. Indeed,
it enhanced TAp63a transcriptional activity when coexpressed in
H1299 p53 null cells (Figure S3E). This demonstrates that, in the
absence of mutant p53, Pin1 does not inhibit p63 but rather it
increases p63 transcriptional activity.
Interestingly, in experiments where Pin1 was overexpressed,
we also observed a consistent increase in transcription of
CCNA2, a known direct target gene of the mutant p53-NF-Y
complex (DiAgostinoetal., 2006) (Figure3E).Overall, these results
show that Pin1 contributes to mutant p53 oncogenic properties
both by potentiating its ability to block p63 transcriptional activity
and by influencing other mutant p53 transcriptional functions.
Pin1/Mutant p53 Axis Activates a Pro-Aggressiveness
Transcriptional Program
To investigate how Pin1 and mutant p53 may globally alter gene
expression, we analyzed the transcription profiles of MDA-MB-
231cells ondepletionof eitherPin1ormutant p53.Unbiasedanal-
ysis of functional annotation (AFA) showed that the same cate-
gories of genes were affected under both conditions (Figure S4A),
implying that Pin1 andmutant p53 are involved in the regulation of
similar cellular processes, including proliferation, motility, cyto-
skeleton dynamics, metabolism and signal transduction (Tables
S3 and S4). In particular, we identified 386 genes that were upre-
gulated and 303 genes that were downregulated by depletion of
either Pin1 or mutant p53, suggesting that a group of genes may
be regulated by the concerted action of these two proteins (Fig-
ure4A). TheeffectofPin1andmutantp53depletionon theexpres-
sion of selected genes was confirmed by qRT-PCR (Figure S4B).
We hypothesized that if the transcriptional program inducedby
mutant p53 and Pin1 contained genes relevant for tumor aggres-
siveness, it could influence breast cancer prognosis. To test this
idea, we analyzed primary tumors for associations between the
expression of genes induced by Pin1 andmutant p53 (i.e., genes
downregulated in our profiling experiments) and disease prog-
nosis, using four independent data sets of breast cancer (Des-
medt et al., 2007; Miller et al., 2005; Pawitan et al., 2005; Sotiriou
et al., 2006), which collectively consist of >800 patients. AmongCancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc. 83
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Figure 3. Pin1 Impacts Mutant p53 Transcriptional Regulation
(A) Left: CoIP of endogenous p63 and mutant p53 from MDA-MB-231 cells transduced with HA-Pin1 (+) retroviral construct or empty vector (). Right: CoIP of
endogenous p63 andmutant p53 fromMDA-MB-231 cells transduced with either a retroviral construct expressing an shRNA targeting Pin1 or a control sequence
(C). NRA, not related antibody. Protein inputs (5% of lysate) are shown below.
(B) CoIP of endogenous p63 and ectopically expressedHA-p53K280 or HA-p53K280-4M inMDA-MB-231 cells by transducing the indicated retroviral constructs.
As a negative control, empty vector () was used. Protein inputs (5% of lysate) are shown below.
(C) qRT-PCR of CCNG2 and Sharp-1 mRNA levels in MDA-MB-231 cells on transduction with empty vector () or HA-Pin1 retroviral construct.
(D) qRT-PCR of CCNG2 and Sharp-1mRNA levels in MDA-MB-231 cells transduced with HA-Pin1 retroviral construct on transfection of either p53 or control (C)
siRNAs.
(E) qRT-PCR of CCNA2mRNA levels in MDA-MB-231 cells on transduction with either empty vector () or HA-Pin1 retroviral construct. (C–E) Error bars indicate
SD (n = 3, *p < 0.001, two-tailed t test).
See also Figure S3.
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ones in both conditions of silencing (31 genes). The Desmedt
data set (Desmedt et al., 2007) was used as a training set to build
a gene rank based on clinical data correlation (Table S5) and we
selected the 10 top scoring genes to define a Pin1/mutant p53
signature (Table S6). Kaplan-Meier survival analysis showed
that expression of these genes significantly correlated with clin-
ical outcome: patients expressing high levels displayed a shorter
time to distant metastasis (TDM) and a reduced overall survival
(OS) (Figure 4B; Figures S4C–S4F).
We next investigated whether these ten genes are regulated
by the concerted action of Pin1 andmutant p53. As shown in Fig-
ure 4C, in MDA-MB-231 cells depleted of endogenous mutant
p53, reintroduction of p53K280, but not of p53K280-4M,
induced the expression of all these genes. More important,
ectopic expression of Pin1 together with p53K280 strongly
enhanced their transcription. On the contrary, when Pin1 was
overexpressed alone or together with p53K280-4M, the expres-
sion of these genes was not affected (Figure 4C).
To dissect the mechanisms by which the concerted action of
Pin1 and mutant p53 enhances transcription, chromatin immu-84 Cancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc.noprecipitation experiments (ChIP) were performed in MDA-
MB-231 cells. As shown in Figure 4D and Figure S4G, mutant
p53 is specifically recruited on the promoters of all the Pin1/
mutant p53 signature genes, whereas on Pin1 depletion its
recruitment was reduced by 2-fold. On the other hand, Pin1
is also present on these promoters, but only in a mutant p53
dependent manner (Figure 4E; Figure S4H). Of note, neither
mutant p53 nor Pin1 were recruited to nonspecific regions on
these promoters. Our data suggest that these genes are direct
targets for transcriptional induction by the Pin1/mutant p53
axis and that Pin1 could be required for the proper interaction
of mutant p53 with functional sites on chromatin. Inspection of
these promoter regions revealed the presence of consensus
binding sites for transcription factors known to interact with
mutant p53, such as Ets-1, NF-Y, Sp1, and VDR (Brosh and
Rotter, 2009) (data not shown). The majority of these genes
appeared to be regulated by Pin1 and mutant p53 also in
MDA-MB-468 cells that express endogenous p53H273 (Fig-
ure S4I), indicating that Pin1 could also affect the transcriptional
activity of other p53 mutants. Importantly, induction of these
genes by Pin1 and mutant p53 did not rely on p63, because their
Cancer Cell
Pin1 Amplifies Mutant p53 Gain of Functionexpression was unaffected by p63 knockdown. An exception to
this behavior was found for DEPDC1, whose expression was
reduced on p63 downregulation (Figure S4J).
To investigate the functional roles of these 10 genes as
mediators of Pin1/mutant p53-dependent cell migration, we
analyzed the effect of their silencing in MDA-MB-231 cells. We
identified six genes that, when depleted, reduced migration
without affecting cell viability (Figure 5A; Figure S5A and Table
S7). Interestingly DEPDC1, which was reported to be involved
in proliferation of bladder cancer cells and to be overexpressed
in breast cancer (Kanehira et al., 2007; Sparano et al., 2009),
showed the strongest effect and had an impact also on invasive-
ness (Figure 5B; Figure S5B). Moreover, when overexpressed in
MDA-MB-231 cells, DEPDC1 enhanced migration and, impor-
tantly, it was able to partially rescue the phenotype caused by
mutant p53 depletion (Figure 5C; Figure S5C). We also analyzed
whether genes downregulated by the Pin1/mutant p53 axis
(Figure S4B) may interfere with this pro-migration phenotype.
Indeed, when Dicer was overexpressed in MDA-MB-231 cells,
it was able to overcome Pin1 induced cell migration (Figure 5D;
Figure S5D).
Collectively, these results show that Pin1 acts in concert with
mutant p53 to reprogram gene expression in tumor cells,
regulating a transcriptional program that entails on one hand
the activation of a previously unknown set of mutant p53 direct
target genes relevant for migration and invasion and on the other
the repression of negative regulators of these processes.
In confirmation of this, simultaneous depletion of either mutant
p53 or Pin1 along with Sharp-1 or CCNG2 exerted only a slight
increase of cell migration in our experimental conditions (data
not shown), as compared to previously published results, where
depletion of these genes was shown to control this phenotype in
a TGF-b dependent way (Adorno et al., 2009).
Pin1 Overexpression and p53 Mutation Modulate
Clinical Outcome in Breast Cancer
We next investigated the association of Pin1 expression and p53
mutation status with clinical outcome in breast cancer. Quantita-
tive immunohistochemistry (IHC) was used to analyze Pin1 and
p53 protein expression in primary breast carcinomas (data not
shown). The status of p53 was analyzed by direct sequencing,
and only tumors bearing either wild-type p53 or missense p53
mutations were included in this study, resulting in a series of
212 cases. Pin1 was overexpressed in 144/212 (68%) cases
whereas missense mutations in TP53 were detected in 46/212
(22%) cases (Table S8). Overall survival (OS) was not associated
with Pin1 overexpression (Figure S6A). However, consistent with
previous observations (Langerød et al., 2007; Olivier et al., 2006),
OS was decreased in cases with missense p53 mutations (Fig-
ure S6B). Remarkably, when we determined OS as a function of
the combination between Pin1 expression and presence of p53
missensemutations, we found that it was significantly decreased
in patients with tumors expressing high levels of Pin1 (high Pin1)
andmutant p53, compared to low Pin1 expression (lowPin1) and
mutant p53, or wild-type p53 cases (Figure 6A).
Moreover, multivariate Cox proportional hazards analysis
showed that the combination of Pin1 overexpression and p53
mutation behaved as an independent predictor of poor clinical
outcome (Figure 6B). The dependence of the prognostic valueof p53 mutation on Pin1 expression levels is further highlighted
by the observation that p53 mutation correlates with shorter
OS only in cases with high Pin1 expression levels (Figures 6C
and 6D). Of note, high Pin1 expression levels and p53 missense
mutation were associated with poor outcome in patients treated
with anthracycline-based adjuvant chemotherapy. Also in this
subgroup the combination of Pin1 overexpression and p53
mutation behaved as an independent prognostic factor
(Figure S6C).
DISCUSSION
Increasing evidence has demonstrated that missense mutations
in the TP53 tumor suppressor gene are associated with tumor
progression and metastasis. It is only recently that the mecha-
nistic aspects of the acquisition of malignant phenotypes by
mutant p53 are being unveiled. Indeed, studies performed in
mutant p53 knockin mice have underscored the requirement of
an oncogenic context to activate mutant p53 function (Lang
et al., 2004; Olive et al., 2004; Terzian et al., 2008). Here, we
provide molecular insights into the causal link between onco-
genic signaling and the acquisition of a tumor promoting
behavior by mutant p53. Indeed, we clearly demonstrated both
in mice and in human cancer cells, that oncogenic signaling,
as mimicked by H-RasV12 overexpression, causes phosphoryla-
tion of mutant p53 on critical sites that are recognized by the
phosphorylation-dependent prolyl isomerase Pin1. Only on
Pin1 mediated isomerization mutant p53 is enabled to fully exert
its malignant activities. Indeed, lack of Pin1 hampers mutant p53
dependent tumorigenesis, strongly suggesting a critical role for
this enzyme in transducing oncogenic signaling to activate
mutant p53 gain of function.
The contribution of Pin1 to mutant p53 activities is further
emphasized by our data from H-RasV12 transduced p53M/M
MEFs, where enhanced tumorigenicity was strictly dependent
on Pin1. Our results suggest that the in vivo cooperation between
Ras and mutant p53 described in mouse models of malignant
skin and pancreatic carcinomas (Caulin et al., 2007; Hingorani
et al., 2005), that leads to increased genomic instability and
metastasis, could also depend on Pin1.
As observed in H-RasV12 transformed MEFs, also in human
breast cancer cells we have shown that aberrant signaling
causes phosphorylation of mutant p53 on critical S/T-P sites,
which promotes its recognition by Pin1 as a necessary step to
unleash mutant p53 dependent migration and invasion. These
phenotypes rely in part on inhibition of the metastasis
suppressor p63 by mutant p53 that has been shown to act as
a molecular switch for TGF-b triggered metastasis (Adorno
et al., 2009). We have found that Pin1 potentiates the complex
formed by Smad2, p63, and mutant p53 suggesting that this
isomerase could function downstream of TGF-b signaling,
contributing to downregulate p63 antimetastatic target genes.
Notably, Pin1 also interacts directly with p63 and enhances
p63 transcriptional activity in the absence of mutant p53. Thus
Pin1 may promote p63 tumor suppressive functions, similarly
to what occurs with the other members of the p53 family (Zacchi
et al., 2002; Mantovani et al., 2004). However, in the presence of
mutant p53 Pin1 contributes to the inhibition of p63 functions by
enhancing p63 interaction with mutant p53. In this condition,Cancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc. 85
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Figure 4. Pin1 and Mutant p53 Reprogram Gene Expression
(A) Venn diagram showing the overlap between genes perturbed by depletion of either Pin1 (siPin1) or mutant p53 (sip53) in MDA-MB-231 cells, red: upregulated
genes, green: downregulated genes.
(B) Kaplan-Meier survival curves of time to distant metastasis (TDM) of breast cancer patients classified according to the expression of the Pin1/mutant p53
signature. Red line: caseswith high expression of the 10 genes, blue line: caseswith low expression of the 10 genes. Left: Desmedt data set (Desmedt et al., 2007)
(c2 = 25.6, p = 4.1 3 107, n = 198, log rank test). Right: Sotiriou data set (Sotiriou et al., 2006) (c2 = 7.2, p = 0.0074, n = 179, log rank test).
(C) Bar graph showing fold change in expression of the Pin1/mutant p53 signature genes or an unaffected control gene (PARP3) analyzed by qRT-PCR in
MDA-MB-231 cells on cotransduction of pMSCV or pMSCV HA-Pin1 with the indicated p53 mutants or empty vector () as a negative control. Endogenous
mutant p53 was depleted as in Figure 2E. (n = 3, *p < 0.001 comparing the expression of each gene from the Pin1/mutant p53 signature between the indicated
conditions, two-tailed t test).
(D) ChIP analysis of mutant p53-bound chromatin (IP p53) from MDA-MB-231 cells on transduction with shRNA vectors targeting endogenous Pin1 (shPin1),
mutant p53 (shp53), or LacZ as a negative control (shLacZ). Chromatin was immunoprecipitated with DO1 antibody or mouse purified IgGs as negative control
(see Figure S4G). Promoter occupancy was analyzed by qRT-PCR and calculated as percentage of input chromatin. (n = 3, *p < 0.013 comparing promoter
occupancy for each gene from the Pin1/mutant p53 signature between the indicated conditions, two-tailed t test).
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Figure 5. Pin1/Mutant p53 Target Genes Affect Cell Migration and Invasion
(A) Wound healing-based siRNA analysis. Left: bar graph showing the percentage of well surface covered by migrating cells 24 hr on silencing of the indicated
genes. Error bars indicate SD (n = 4, ***p < 0.001 relative to LacZ siRNA, two-tailed t test). Right: representative images of the assay. Scale bar represents 1 mm.
(B) Transwell migration assays of MDA-MB-231 cells on DEPDC1 depletion using two different siRNA sequences (A and B). Error bars indicate SD (n = 3,
*p < 0.001). See Figure S5B for qRT-PCR analysis of DEPDC1 depletion.
(C) Transwell migration assays performed in MDA-MB-231 cells transfected with vectors expressing two DEPDC1 isoforms (DEPDC1-1 and DEPDC1-2) on
control (C) or mutant p53 siRNA transfection. As a negative control empty vector was used (). Error bars indicate SD (n = 3, *p < 0.01). See Figure S5C for
a western blot analysis of cell lysates.
(D) Transwell migration assays performed in MDA-MB-231 cells transfected with pcDNA3 Dicer or empty vector () as a control, on transduction with retroviral
constructs pMSCV HA-Pin1 or empty vector. Error bars indicate SD (n = 3, *p < 0.005). See Figure S5D for western blot analysis of cell lysates.
See also Figure S5 and Table S7.
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Pin1 Amplifies Mutant p53 Gain of Functionbesides inhibiting p63 target genes such as CCNG2, Sharp-1,
andDicer, we have shown that Pin1 andmutant p53 also repress
the expression of several other genes known to counteract
tumor formation and progression like TIMP3 (Anania et al.,
2011; Song et al., 2010), CAV1 (Bouras et al., 2004), and
HPGD (Wolf et al., 2006).
In addition to the repression of the above mentioned genes,
we have demonstrated that the Pin1/mutant p53 axis must
also induce a specific set of genes to fully establish malignant
phenotypes (Figure 7). Among this group we identified 10mutant
p53 direct target genes, as evidenced by our ChIP experiments.
The regions analyzed on these promoters contain consensus
binding sites for transcription factors previously shown to tether
mutant p53 on cognate promoters and to contribute to mutant
p53 gain of function, such as Ets-1, NF-Y, Sp1, and VDR (Brosh
and Rotter, 2009). The evidence that Pin1 depletion hampers
mutant p53 recruitment on chromatin suggests that Pin1 could
be required for the proper interaction of mutant p53 with these(E) ChIP analysis of Pin1-bound chromatin (IP Pin1) fromMDA-MB-231 cells on tra
(shp53), or lacZ as a negative control (shLacZ). Chromatin was immunoprecipit
(see Figure S4H). Promoter occupancy was analyzed as in (D). (D and E) As a co
analyzed (nonspecific region). (C–E) Error bars indicate SD (n = 3, two-tailed t te
See also Figure S4 and Tables S3–S6.transcriptional partners on specific gene promoters. Nine of
these ten genes were unaffected by p63 downregulation in our
cellular system, indicating that the Pin1/mutant p53 axis
promotes aggressiveness by at least two independent but
complementary mechanisms. A notable exception was
DEPDC1, whose expression was partially reduced in this condi-
tion. In silico inspection revealed the presence of a p63 binding
site at 27 kb from DEPDC1 transcription start site. We specu-
late that p63 may positively regulate DEPDC1 expression,
possibly through still uncharacterized mechanisms that could
involve its interaction with mutant p53.
The relevance of these 10 genes (Pin1/mutant p53 signature)
for the metastatic phenotype was supported by their activity as
key effectors of mutant p53-dependent migration and invasion
and by their significant correlation with clinical outcome found
in four independent breast cancer data sets. Interestingly, three
of these genes,CCNE2,BUB1, andCENPA are present in a gene
signature predictive of early metastasis in breast cancer (van’tnsductionwith shRNA vectors targeting endogenous Pin1 (shPin1), mutant p53
ated with Pin1 polyclonal antibody or rabbit purified IgGs as negative control
ntrol of specificity, a promoter region not bound by mutant p53 nor Pin1 was
st).
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Figure 6. High Pin1 Levels Influence the Prognostic Value of p53 Missense Mutation in Breast Cancer
(A) Kaplan-Meier survival curves of breast cancer patients (observation threshold 10 years, clinical variable = OS) as a function of the combination of Pin1
overexpression and presence of p53missense mutations. Low Pin1, tumors not overexpressing Pin1; high Pin1, tumors overexpressing Pin1 (c2 = 17.2, p < 104,
n = 212, log rank test).
(B) Multivariate analysis of risk of death. Multivariate analysis was performed on the same cohort of patients analyzed in (A) using Cox proportional hazards
regression modeling. The relationships between survival and high Pin1 levels and TP53missense mutation or other clinical variables used in the clinical practice
are shown.
(C) Kaplan-Meier survival curves of breast cancer patients with high expression of Pin1 (observation threshold 10 years, clinical variable = OS) as a function of the
presence of missense mutant or wild-type p53 (c2 = 14.1, p < 104, n = 143, log rank test).
(D) Kaplan-Meier survival curves of breast cancer patients with low expression of Pin1 (observation threshold 10 years, clinical variable = OS) as a function of the
presence of missense mutant or wild-type p53 (c2 = 0.4, p = 0.548, n = 69, log rank test).
See also Figure S6 and Table S8.
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Pin1 Amplifies Mutant p53 Gain of FunctionVeer et al., 2002). In addition, C21orf45 was shown to sustain
tumor cell addiction to oncogenic K-Ras (Luo et al., 2009),
whereas CPSF6 was found both upregulated by Snail in human
colon cancer and fused to FGFR1 in hematological malignancies
(Hidalgo-Curtis et al., 2008; Larriba et al., 2010).
A further demonstration of the clinical relevance of the Pin1/
mutant p53 axis was provided by our results in a cohort of breast
cancer patients. This analysis revealed that the prognostic value
of p53 mutation was strongly improved by combining it with
quantification of Pin1 protein levels. Studies including larger
numbers of cases are required to validate this combination as
a prognostic and potentially predictive tool. Nevertheless, multi-
variate analysis showed that concomitant high Pin1 expression
and p53 mutation behaved as an independent and strong
predictor of clinical outcome. Indeed, in tumors overexpressing
Pin1, p53 status allowed a better stratification of patients into
groups of long- or short-term overall survival and this was also
observed among patients who received anthracycline-based
adjuvant chemotherapy.
Our data suggest that patients bearing high Pin1 levels and
mutant p53 could benefit from inhibition of the Pin1/mutant
p53 axis. Proposed strategies based on inactivation of mutant
p53 are represented by small molecules that reactivate wild-
type like functions (Selivanova and Wiman, 2007), or peptide
aptamers that kill cancer cells expressing mutant p53 (Guida88 Cancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc.et al., 2008). By dissecting upstream and downstreammolecular
mechanisms that impinge on mutant p53 function we identified
additional potential targets for clinical intervention such as Pin1
or the kinases acting on mutant p53, as well as downstream
effectors of the Pin1/mutant p53 axis.
Mutations in TP53 are frequent in basal-like breast cancer
(Langerød et al., 2007), a subgroup of tumors consisting mostly
of estrogen receptor-, progesterone receptor-, andHer2-negative
(triple-negative) immunohistochemical phenotype, that have
ahigher riskof recurrenceandwhosemanagement still represents
a clinical challenge. Someof the Pin1/mutant p53 signature genes
(e.g., BUB1, CENPA, and DEPDC1), that we found modulated in
two triple negativebreast cancercell lines, arealsooverexpressed
in triple negative breast cancers (Sparano et al., 2009). Therefore
our findings carry therapeutic implications for this subtype of
breast cancer and potentially also for other epithelial cancers
bearing mutant p53 and high levels of Pin1.
EXPERIMENTAL PROCEDURES
Additional methods can be found in the Supplemental Experimental
Procedures.
Mice Strains and Analysis
Mouse cohorts were generated by mating p53M/+ or p53+/ with Pin1+/ mice
maintained on a C57BL/6 background and genotyping was performed by
Pin1 
Oncogenic signaling  
Inhibition of growth and 
metastasis suppressor genes 
Activation of a pro-aggressiveness 
transcriptional program 
TA 
TF 
Pin1 
Pin1 
Kinases 
p63 
mp53 
P
mp53 
P
mp53 
P
mp53 
P
Pin1 
Figure 7. Schematic Representation Summarizing the Proposed
Mechanism of the Concerted Action of Pin1 and Mutant p53 in the
Promotion of an Aggressive Tumor Phenotype
P, phosphate group; TA, transcriptional activator; TF, transcription factor.
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Pin1 Amplifies Mutant p53 Gain of Functionpolymerase chain reaction (PCR) analysis as described (Atchison et al., 2003;
Lang et al., 2004). Animals showing signs of illness or evident tumor burden
were sacrificed and organs were fixed in 10% formalin/PBS for 24 hr. Tissues
wereembedded inparaffin, sectionedat5mm,dewaxed,andstainedwithhema-
toxylin and eosin (H&E) before pathological analysis. Procedures involving
animals conformed to institutional guidelines that comply with international
laws and policies (UKCCCR, 1989). All experimental protocols were approved
by the Animal Ethics Committee of the athenaeum of the University of Trieste.
Transformation Assays and In Vivo Tumorigenicity
Low-passage MEFs infected with pLPC H-RasV12 or empty vector were resus-
pended in DMEM supplemented with 10% fetal bovine serum, penicillin
(100 IU/ml) and streptomycin (100 IU/ml), containing 0.3% agarose and plated
on top of 1% agarose in the same medium, at a cell density of 13 105 for each
60-mm plate. After 14 days in culture, colonies reaching at least 100 mm were
scored. Experiments were performed in triplicate using at least two different
clones for each genotype. To assess tumorigenicity of H-RasV12, infected
MEFs 1 3 106 cells were injected subcutaneously on both sides in NOD
SCID mice and after 2 weeks tumor volume was determined by caliper
measurements as described (Rustighi et al., 2009). Procedures involving
animals and their care were in conformity with institutional guidelines
(D.L. 116/92 and subsequent complementing circulars) and all experimental
protocols were approved by the Animal Ethics Committee of the athenaeum
of the University of Trieste.
Migration and Invasion Assays
For wound healing assays, transfected cells were plated on 35-mm plates and
cultured to 90% confluence. Cells were scraped with a 200 ml tip and wound
closure was followed for 36 hr. For transwell migration assays 24-well PET
inserts were used (8.0 mm pore size, Falcon). Invasion assays were performed
in 24-well PET inserts (8.0 mm pore size, Falcon) with matrigel-coated filters.
In Vivo Metastasis Assays
For lung colonization assaysMDA-MB-231cells were cotransducedwith a len-
tiviral vector coding for the Firefly Luciferase reporter gene and pSR shLacZ or
pSR shPin1 (six animals per group). 13 106 cells were resuspended in 100 ml ofPBS and inoculated in the tail vein of SCID mice. For in vivo imaging biolumi-
nescence images were acquired at several time points after cell injection using
a cooled charge-coupled device camera mounted on a light-tight specimen
box (IVIS Lumina II Imaging System; Caliper Life Sciences, Alameda, CA).
Tenminutes before imaging, anesthetized animals were administered intraper-
itoneally with 150mg/kg D-luciferin (Caliper Life Sciences) in PBS. Histological
analysis was carried out 1 month after MDA-MB-231 cells injection on paraffin
embedded lungs by H&E staining. For computer-aided assessment of lung
tissue, the area occupied by metastatic foci, identifiable in sections of lung
lobes, were calculated using a LeicaDM200microscope equippedwith a Leica
DFC295 digital color camera and the software Leica Application Suite (LAS)
V3, summed, and total value was finally compared to the whole area of the
lung lobe. IHC detection of Pin1 expression was carried out using Pin1
monoclonal antibody (see Supplemental Experimental Procedures). Proce-
dures involving animals and their care were in conformity with institutional
guidelines (D.L. 116/92 and subsequent complementing circulars) and all
experimental protocols were approved by the ethical Committee of the Univer-
sity of Padua (CEASA).
Gene Expression Analysis
Total RNA was extracted using Trizol reagent (Invitrogen) and subjected to
DNase-I (Ambion) treatment. For microarray analysis three biological mRNA
replicates for each group (siPin1 or sip53) were hybridized on Affymetrix
GeneChip Human Genome U133A 2.0 array. For quantitative RT-PCR
mRNA was transcribed using Superscript III (Invitrogen). Real-time PCR was
performed using SYBR Green PCR master mix (Applied Biosystems) and
StepOne Plus cycler (Applied Biosystems). Primer sequences are shown in
the Supplemental Experimental Procedures.
Survival Analysis for Gene Rankings
Cox proportional hazards model was fitted to test the association between
gene expression of 31 common top downregulated genes and survival
(Desmedt data set GSE7390). From the clinical associated rank, we selected
genes with score >3, obtaining in this way the 10-gene signature. To verify
the correlation of the 10-gene signature and breast cancer clinical data,
a Mantel-Haenszel test was applied to the other normalized data sets we
used (GSE2990, GSE3494, GSE1456) (survival R package).
Chromatin Immunoprecipitation
Chromatin was immunoprecipitated with p53 DO1 (Santa Cruz) or polyclonal
Pin1 antibody (Zacchi et al., 2002). As negative controls IgGs purified from
rabbit or mouse serum were used. For a detailed protocol see Supplemental
Experimental Procedures. Coimmunoprecipitated DNA was analyzed by
real-time PCR on a StepOne Plus cycler (Applied Biosystems), using SYBR
Green Universal PCR Master Mix (Applied Biosystems). Promoter occupancy
was calculated as percent of input chromatin immunoprecipitated using the
2DCt method. Primer sequences are shown in the Supplemental Experimental
Procedures.
Tissue Microarray Survival Data Analysis
The tissue microarray (TMA) used in this study consisted only of historical
breast cancer samples, donated from each of 212 primary previously
untreated and otherwise unselected tumors. The results generated were ex-
ported via Aperio Web Services. Overall survival was calculated from date of
treatment start to date of death, or date of censor if alive. Survival curves
were constructed using Kaplan-Meier methodology. Log rank tests assessed
differences in tumor characteristics. Adjuvant chemotherapy typically con-
sisted on anthracycline-based regimens. Breast cancer samples were
collected and formed into a TMA by the Tayside Tissue Bank (http://www.
tissuebank.dundee.ac.uk) under delegated ethical authority of the Tayside
Local Research Ethics Committee with written informed consent from contrib-
uting patients.
Multivariate Analysis Using a Cox Proportional Hazards Model
The analysis of the death risk for the 212 tumors from the TMA was conducted
using Cox proportional hazards regression modeling. We examined the rela-
tionship between overall survival and the presence of TP53missense mutation
and Pin1 levels and other predictors commonly used in the clinical practice,Cancer Cell 20, 79–91, July 12, 2011 ª2011 Elsevier Inc. 89
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Pin1 Amplifies Mutant p53 Gain of Functionincluding tumor size, estrogen receptor status (ER status), progesterone
receptor status (PGR status), nodal status, HER2 status, node infiltration,
and tumor grade. We fitted Cox proportional hazards regression model first
by using clinical variables only and then adding TP53 missense mutation
and Pin1 level variables. Clinical parameters were treated as follows:
Tumor size: continuous variable;
Tumor grade: grade 1, grade 2, grade 3;
Node infiltration: negative if%4 (0), positive >4 (1);
ER status: negative if%4 (1), positive >4 (0);
PGR status: negative if%4 (1), positive > 4 (0)
HER2 status: positive staining or negative staining (0, 1); and
Pin1 status: positive nuclear staining of Pin1 >5 (1), negative if%5 (0).ACCESSION NUMBERS
The accession number in the Gene Expression Omnibus public database for
the MDA-MB-231 expression array experiment is GSE26262.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, eight tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2011.06.004.
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